ALGS Aligos Therapeutics Inc

USD 0.56 0.06 11.078023
Icon

Aligos Therapeutics Inc (ALGS) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.56

+0.06 (+11.08)%

USD 0.04B

0.40M

N/A

USD 2.00 (+257.46%)

Icon

ALGS

Aligos Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 0.56
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.04B

USD 2.00 (+257.46%)

USD 0.56

Aligos Therapeutics Inc (ALGS) Stock Forecast

N/A

Based on the Aligos Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Aligos Therapeutics Inc is not available over the next 12 months. Aligos Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Aligos Therapeutics Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Aligos Therapeutics Inc’s stock price was USD 0.5595. Aligos Therapeutics Inc’s stock price has changed by +9.73% over the past week, +24.06% over the past month and -41.41% over the last year.

No recent analyst target price found for Aligos Therapeutics Inc
No recent average analyst rating found for Aligos Therapeutics Inc

Company Overview Aligos Therapeutics Inc

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical tri...Read More

https://www.aligos.com

One Corporate Drive, South San Francisco, CA, United States, 94080

67

December

USD

USA

Adjusted Closing Price for Aligos Therapeutics Inc (ALGS)

Loading...

Unadjusted Closing Price for Aligos Therapeutics Inc (ALGS)

Loading...

Share Trading Volume for Aligos Therapeutics Inc Shares

Loading...

Compare Performance of Aligos Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ALGS

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Aligos Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +4.34 (+0.88%) USD126.85B 31.94 20.00

ETFs Containing ALGS

Symbol Name ALGS's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Aligos Therapeutics Inc (ALGS) Stock

Stock Target Advisor's fundamental analysis for Aligos Therapeutics Inc's stock is Bearish.

Unfortunately we do not have enough data on ALGS's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on ALGS's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on ALGS's stock to indicate if its overvalued.

The last closing price of ALGS's stock was USD 0.56.

The most recent market capitalization for ALGS is USD 0.04B.

Unfortunately we do not have enough analyst data on ALGS's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Aligos Therapeutics Inc's stock.

As per our most recent records Aligos Therapeutics Inc has 67 Employees.

Aligos Therapeutics Inc's registered address is One Corporate Drive, South San Francisco, CA, United States, 94080. You can get more information about it from Aligos Therapeutics Inc's website at https://www.aligos.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...